{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT01999361",
            "orgStudyIdInfo": {
                "id": "20071058"
            },
            "organization": {
                "fullName": "University of Miami",
                "class": "OTHER"
            },
            "briefTitle": "Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss",
            "officialTitle": "Myfortic\u00ae Monotherapy to Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss",
            "therapeuticArea": [
                "Endocrinology"
            ],
            "study": "prevention-of-de-novo-allosensitization-in-islet-transplant-recipients-following-complete-graft-loss"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-01",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2009-01"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2013-11-25",
            "studyFirstSubmitQcDate": "2013-11-25",
            "studyFirstPostDateStruct": {
                "date": "2013-12-03",
                "type": "ESTIMATED"
            },
            "lastUpdateSubmitDate": "2024-01-29",
            "lastUpdatePostDateStruct": {
                "date": "2024-01-31",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR_INVESTIGATOR",
                "investigatorFullName": "Rodolfo Alejandro",
                "investigatorTitle": "Professor of Medicine",
                "investigatorAffiliation": "University of Miami"
            },
            "leadSponsor": {
                "name": "Rodolfo Alejandro",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false
        },
        "descriptionModule": {
            "briefSummary": "This is a single-center, prospective, open label study in islet transplant recipients after complete islet graft rejection/loss, defined as stimulated c-peptide \u22640.3 ng/mL.",
            "detailedDescription": "After complete islet graft loss is determined, patient's maintenance immunosuppression (i.e. sirolimus and tacrolimus) will be discontinued and they will be placed on Myfortic\u00ae monotherapy for 2 years thereafter. After completion of two years of Myfortic\u00ae maintenance monotherapy, it will be weaned and subjects will be monitored over the subsequent twelve months, for the appearance of sensitization using panel reactive antibody (PRA) levels."
        },
        "conditionsModule": {
            "conditions": [
                "Type 1 Diabetes Mellitus"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "PREVENTION",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 18,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Myfortic treatment",
                    "type": "EXPERIMENTAL",
                    "description": "Treatment with Myfortic",
                    "interventionNames": [
                        "Drug: Myfortic"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Myfortic",
                    "description": "treatment with myfortic",
                    "armGroupLabels": [
                        "Myfortic treatment"
                    ],
                    "otherNames": [
                        "mycophenolic acid"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "allosensitization after complete islet graft loss",
                    "description": "Allosensitization after complete islet graft loss after completion of two years of Myfortic\u00ae maintenance monotherapy.",
                    "timeFrame": "3 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Male and female patients age 18-70 years of age.\n2. Ability to provide written informed consent.\n3. Mentally stable and able to comply with the procedures of the study protocol.\n4. Any subject currently prescribed immunosuppressive medications or discontinuation of immunosuppressive medications indicated as per current protocol of islet transplantation.\n5. History of at least one islet transplant.\n6. Stimulated C-peptide \\<0.3 ng/ml.\n\nExclusion Criteria:\n\n1. Known history of untreated severe hyperlipidemia, obesity, or refractory hypertension\n2. For female participants: Positive pregnancy test or presently breast-feeding.\n3. History of active infection including hepatitis B, hepatitis C, HIV, or TB.\n4. Any history of malignancy except for completely resected squamous or basal skin cell carcinoma.\n5. Known active alcohol or substance abuse.\n6. Severe co-existing history of cardiac disease, characterized by a history of any one of these conditions: recent myocardial infarction (within past 6 months), evidence of ischemia on functional cardiac exam within the last year, or left ventricular ejection fraction \\<30%.\n7. History of persistent elevation of liver function tests. SGOT (AST), SGPT (ALT), alkaline phosphatase or total bilirubin, with values \\>1.5 times normal upper limits will exclude a patient.\n8. Evidence of inter-current infection.\n9. Active peptic ulcer disease\n10. History on non-adherence to prescribed regimens including immunosuppression.\n11. PRA \u2265 50% or evidence of significant sensitization to be determined at discretion of the investigator.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "70 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "overallOfficials": [
                {
                    "name": "Rodolfo Alejandro, MD",
                    "affiliation": "University of Miami",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Diabetes Research Institute",
                    "status": "RECRUITING",
                    "city": "Miami",
                    "state": "Florida",
                    "zip": "33136",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Rodolfo Alejandro, MD",
                            "role": "CONTACT",
                            "phone": "305-243-5321",
                            "email": "islet@med.miami.edu"
                        },
                        {
                            "name": "Ana M Alvarez, APRN",
                            "role": "CONTACT",
                            "phone": "305 243-3389",
                            "email": "axa383@med.miami.edu"
                        },
                        {
                            "name": "Rodolfo Alejandro, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "David A Baidal, MD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 25.77427,
                        "lon": -80.19366
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "33481552",
                    "type": "DERIVED",
                    "citation": "Rios P, Baidal D, Lemos J, Camhi SS, Infante M, Padilla N, Alvarez Gil AM, Fuenmayor V, Ambut J, Qasmi FA, Mantero AM, Cayetano SM, Ruiz P, Ricordi C, Alejandro R. Long-term Persistence of Allosensitization After Islet Allograft Failure. Transplantation. 2021 Nov 1;105(11):2490-2498. doi: 10.1097/TP.0000000000003635."
                }
            ],
            "seeAlsoLinks": [
                {
                    "label": "Diabetes Research Institute clinical trials",
                    "url": "https://diabetesresearch.org/dri-clinical-trials/"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003922",
                    "term": "Diabetes Mellitus, Type 1"
                }
            ],
            "ancestors": [
                {
                    "id": "D000003920",
                    "term": "Diabetes Mellitus"
                },
                {
                    "id": "D000044882",
                    "term": "Glucose Metabolism Disorders"
                },
                {
                    "id": "D000008659",
                    "term": "Metabolic Diseases"
                },
                {
                    "id": "D000004700",
                    "term": "Endocrine System Diseases"
                },
                {
                    "id": "D000001327",
                    "term": "Autoimmune Diseases"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M7117",
                    "name": "Diabetes Mellitus, Type 1",
                    "asFound": "Type 1 Diabetes Mellitus",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7115",
                    "name": "Diabetes Mellitus",
                    "relevance": "LOW"
                },
                {
                    "id": "M11639",
                    "name": "Metabolic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M25403",
                    "name": "Glucose Metabolism Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M7862",
                    "name": "Endocrine System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M4629",
                    "name": "Autoimmune Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009173",
                    "term": "Mycophenolic Acid"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000903",
                    "term": "Antibiotics, Antineoplastic"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000000904",
                    "term": "Antibiotics, Antitubercular"
                },
                {
                    "id": "D000000995",
                    "term": "Antitubercular Agents"
                },
                {
                    "id": "D000000900",
                    "term": "Anti-Bacterial Agents"
                },
                {
                    "id": "D000000890",
                    "term": "Anti-Infective Agents"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12128",
                    "name": "Mycophenolic Acid",
                    "asFound": "Transgender",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4222",
                    "name": "Anti-Bacterial Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4224",
                    "name": "Antibiotics, Antitubercular",
                    "relevance": "LOW"
                },
                {
                    "id": "M4311",
                    "name": "Antitubercular Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4214",
                    "name": "Anti-Infective Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}